Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DENEB: Development of new criteria for curability after local excision of pathological T1 colorectal cancer using liquid biopsy.
Miyo M, Kato T, Nakamura Y, Taniguchi H, Takahashi Y, Ishii M, Okita K, Ando K, Yukami H, Mishima S, Yamazaki K, Kotaka M, Watanabe J, Oba K, Aleshin A, Billings PR, Rabinowitz M, Kotani D, Oki E, Takemasa I, Mori M, Yoshino T. Miyo M, et al. Among authors: oba k. Cancer Sci. 2022 Apr;113(4):1531-1534. doi: 10.1111/cas.15226. Epub 2022 Feb 28. Cancer Sci. 2022. PMID: 34839585 Free PMC article.
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Mishima H, et al. Among authors: oba k. Jpn J Clin Oncol. 2012 Feb;42(2):134-8. doi: 10.1093/jjco/hyr180. Epub 2011 Dec 12. Jpn J Clin Oncol. 2012. PMID: 22167662 Free PMC article. Clinical Trial.
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. Hazama S, et al. Among authors: oba k. Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27. Cancer Sci. 2013. PMID: 24033692 Free PMC article. Clinical Trial.
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y. Komatsu Y, et al. Among authors: oba k. Cancer Sci. 2015 Jul;106(7):891-5. doi: 10.1111/cas.12675. Epub 2015 May 27. Cancer Sci. 2015. PMID: 25872578 Free PMC article. Clinical Trial.
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Kotaka M, et al. Among authors: oba k. Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16. Cancer Chemother Pharmacol. 2015. PMID: 25983021 Free PMC article. Clinical Trial.
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H. Soda H, et al. Among authors: oba k. BMC Cancer. 2015 Oct 14;15:695. doi: 10.1186/s12885-015-1685-z. BMC Cancer. 2015. PMID: 26467662 Free PMC article. Clinical Trial.
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.
Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T. Aoyama T, et al. Among authors: oba k. Cancer Med. 2017 Jul;6(7):1573-1580. doi: 10.1002/cam4.1126. Epub 2017 Jun 22. Cancer Med. 2017. PMID: 28639738 Free PMC article.
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials.
Maeda H, Kashiwabara K, Aoyama T, Oba K, Honda M, Mayanagi S, Kanda M, Hamada C, Sadahiro S, Sakamoto J, Saji S, Yoshikawa T. Maeda H, et al. Among authors: oba k. J Cancer. 2017 Oct 23;8(19):4057-4064. doi: 10.7150/jca.21365. eCollection 2017. J Cancer. 2017. PMID: 29187881 Free PMC article.
568 results